Proton Pump Inhibitors Linked to Higher Mortality Risk

Share this content:
Proton Pump Inhibitors Linked to Higher Mortality Risk
Proton Pump Inhibitors Linked to Higher Mortality Risk

WEDNESDAY, July 5, 2017 (HealthDay News) -- Proton pump inhibitors (PPIs) may increase risk of premature mortality when taken for extended periods, according to research published online July 4 in BMJ Open.

Ziyad Al-Aly, M.D., assistant professor of medicine with the Washington University School of Medicine in St. Louis, and colleagues compared the medical records of 275,977 users of PPIs against those of 73,335 patients who took histamine 2 (H2) blockers.

The researchers found that patients taking PPIs for a year or more had a 51 percent increased risk of premature death, compared with 31 percent for patients on the drugs for six months to a year, and 17 percent for three- to six-month users. Overall, PPI users have a 25 percent increased risk of premature death compared with patients taking H2 blockers. The researchers calculated that for every 500 people taking PPIs for a year, there is one death that would not have occurred otherwise, Al-Aly told HealthDay.

"There was a relationship between duration of use and risk of death," Al-Aly said. "More prolonged use was associated with even higher risk."

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Global Prevalence of Insufficient Activity 27.5 Percent

Global Prevalence of Insufficient Activity 27.5 Percent

Levels of insufficient physical activity stable between 2001, 2016; increase seen in high-income countries

HTN Tx Intensification Common Upon Discharge in U.S. Vets

HTN Tx Intensification Common Upon Discharge in U.S. ...

Fourteen percent of older adults admitted to hospital for non-cardiac conditions had intensification of tx

Quarterly Canakinumab Reduces Risk for Gout Attacks

Quarterly Canakinumab Reduces Risk for Gout Attacks

Doesn't affect serum uric acid levels over time, but targets interleukin-1β

is free, fast, and customized just for you!




Already a member?

Sign In Now »